Potency evaluated against NNRTI-Resistant HIV-1 strain Gly190Ala
|
Human immunodeficiency virus 1
|
1.0
nM
|
|
Potency evaluated against NNRTI-Resistant HIV-1 strain Leu100Ile
|
Human immunodeficiency virus 1
|
16.0
nM
|
|
Potency evaluated against NNRTI-Resistant HIV-1 strain Lys103Asn
|
Human immunodeficiency virus 1
|
4.0
nM
|
|
Potency evaluated against NNRTI-Resistant HIV-1 strain Tyr181Cys
|
Human immunodeficiency virus 1
|
8.0
nM
|
|
Potency evaluated against NNRTI-Resistant HIV-1 strain Tyr188Leu
|
Human immunodeficiency virus 1
|
40.0
nM
|
|
Potency evaluated against NNRTI-Resistant HIV-1 strain Val106Ala
|
Human immunodeficiency virus 1
|
3.0
nM
|
|
Potency evaluated against wild type HIV-1 strain IIIB
|
Human immunodeficiency virus 1
|
1.0
nM
|
|
Inhibitory activity against 100I strain of HIV-I in MT-4 cells
|
Human immunodeficiency virus 1
|
18.0
nM
|
|
Inhibitory activity against 103N strain and 181C strain of HIV-I in MT-4 cells
|
Human immunodeficiency virus 1
|
44.0
nM
|
|
Inhibitory activity against 103N strain of HIV-I in MT-4 cells
|
Human immunodeficiency virus 1
|
4.3
nM
|
|
Inhibitory activity against 181C strain of HIV-I in MT-4 cells
|
Human immunodeficiency virus 1
|
7.5
nM
|
|
Inhibitory activity against 188L strain of HIV-I in MT-4 cells
|
Human immunodeficiency virus 1
|
48.0
nM
|
|
Inhibitory activity against LAI strain of HIV-I in MT-4 cells
|
Human immunodeficiency virus 1
|
1.0
nM
|
|
Effective concentration against human immunodeficiency virus type 1 wild type strain
|
Human immunodeficiency virus 1
|
1.2
nM
|
|
Effective concentration against human immunodeficiency virus type 1Y181C mutant strain
|
Human immunodeficiency virus 1
|
7.0
nM
|
|
Effective concentration against human immunodeficiency virus type 1 G190S mutant strain
|
Human immunodeficiency virus 1
|
2.0
nM
|
|
Effective concentration against human immunodeficiency virus type 1 L100I mutant strain
|
Human immunodeficiency virus 1
|
11.0
nM
|
|
Effective concentration against human immunodeficiency virus type 1 Y188L mutant strain
|
Human immunodeficiency virus 1
|
37.0
nM
|
|
Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells
|
Homo sapiens
|
1.0
nM
|
|
Effective concentration against human immunodeficiency virus type 1 in K103N mutant strain
|
Human immunodeficiency virus 1
|
2.0
nM
|
|
Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells
|
Homo sapiens
|
4.0
nM
|
|
Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells
|
Homo sapiens
|
18.0
nM
|
|
Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells
|
Homo sapiens
|
8.0
nM
|
|
Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells
|
Homo sapiens
|
48.0
nM
|
|
Effective concentration of the compound to inhibit HIV-1 mutant K103N+Y181C replication in HIV-infected MT-4 cells
|
Homo sapiens
|
44.0
nM
|
|
Effective concentration against rhuman immunodeficiency virus type 1 K103N and Y181C mutant strains
|
Human immunodeficiency virus 1
|
54.0
nM
|
|
Antiviral activity against HIV1 NL4-3 infected in human TZM-bl cells assessed as inhibition of viral replication
|
Human immunodeficiency virus 1
|
0.62
nM
|
|
Antiviral activity against HIV1 RTMDR1 infected in human TZM-bl cells assessed as inhibition of viral replication
|
Human immunodeficiency virus 1
|
0.298
nM
|
|
Inhibition of RNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase by filter-based filtration assay
|
Human immunodeficiency virus 1
|
19.0
nM
|
|
Inhibition of RNA-dependent DNA polymerase activity of HIV1 subtype B reverse transcriptase M230L mutant by filter-based filtration assay
|
Human immunodeficiency virus 1
|
172.0
nM
|
|
Inhibition of DNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase by gel-based primer extension assay
|
Human immunodeficiency virus 1
|
131.0
nM
|
|
Antiviral activity against HIV 1 subtype B harboring wild type reverse transcriptase infected in human TZM-bl cells assessed as inhibition of viral growth by luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
0.91
nM
|
|
Antiviral activity against HIV 1 subtype B harboring reverse transcriptase M230L mutant infected in human TZM-bl cells assessed as inhibition of viral growth by luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
5.8
nM
|
|
Antiviral activity against HIV-1 Bal infected in human TZM-bl cells after 7 days by RT assay
|
Human immunodeficiency virus 1
|
2.2
nM
|
|
Antiviral activity against HIV-1 Bal infected in human PM1 cells after 7 days by RT assay
|
Human immunodeficiency virus 1
|
6.0
nM
|
|
Antiviral activity against HIV-1 Bal infected in human monocyte derived macrophages after 7 days by RT assay
|
Human immunodeficiency virus 1
|
2.4
nM
|
|
Antiviral activity against HIV-1 3B infected in human TZM-bl cells after 7 days by RT assay
|
Human immunodeficiency virus 1
|
1.0
nM
|
|
Antiviral activity against HIV-1 3B infected in human MT4 cells after 7 days by RT assay
|
Human immunodeficiency virus 1
|
0.9
nM
|
|
Antiviral activity against HIV-1 RF infected in human PM1 cells after 7 days by RT assay
|
Human immunodeficiency virus 1
|
2.4
nM
|
|
Antiviral activity against HIV-1 Bal infected in human TZM-bl cells after 24 hrs by luciferase reporter gene assay
|
Human immunodeficiency virus 1
|
1.46
nM
|
|
Antiviral activity against HIV-1 Bal infected in human TZM-bl cells after 24 hrs by luciferase reporter gene assay in presence of 12.5% whole semen
|
Human immunodeficiency virus 1
|
1.75
nM
|
|
Antiviral activity against HIV-1 Bal infected in human TZM-bl cells after 24 hrs by luciferase reporter gene assay in presence of 12.5% cervical mucus
|
Human immunodeficiency virus 1
|
8.32
nM
|
|
Antiviral activity against HIV-1 Bal infected in 1 hr compound pretreated human ectocervical explant tissue assessed as inhibition of viral replication by RT-PCR
|
Human immunodeficiency virus 1
|
0.2
nM
|
|
Antiviral activity against HIV-1 Bal infected in 1 hr compound pretreated human ectocervical explant tissue assessed as inhibition of provirus formation at 1 nM by RT-PCR
|
Human immunodeficiency virus 1
|
99.0
%
|
|
Antiviral activity against HIV-1 Bal infected in human PM1 cells assessed as inhibition of transmission of virus to premissive T cells
|
Human immunodeficiency virus 1
|
0.1
nM
|
|
Antiviral activity against HIV-1 Bal infected in human PM1 cells assessed as inhibition of transmission of virus to premissive T cells at 10 uM
|
Human immunodeficiency virus 1
|
90.0
%
|
|
Antiviral activity against HIV-1 Bal infected in 2 hrs 100 nM compound pretreated human ectocervical explant tissue assessed as prolonged inhibition of viral infection post compound removal
|
Human immunodeficiency virus 1
|
90.0
%
|
|
Antiviral activity against HIV-1 Bal infected in 2 hrs 1000 nM compound pretreated human ectocervical explant tissue assessed as prolonged inhibition of viral infection post compound removal measured after 2 days post compound removal
|
Human immunodeficiency virus 1
|
90.0
%
|
|
Antiviral activity against HIV-1 Bal infected in 2 hrs 10000 nM compound pretreated human ectocervical explant tissue assessed as prolonged inhibition of viral infection post compound removal measured after 4 days post compound removal
|
Human immunodeficiency virus 1
|
90.0
%
|
|
Antiviral activity against HIV-1 Bal infected in 2 hrs 10000 nM compound pretreated human ectocervical explant tissue assessed as prolonged inhibition of viral infection post compound removal measured after 6 days post compound removal
|
Human immunodeficiency virus 1
|
80.0
%
|
|
Antiviral activity against HIV-1 Bal infected in 24 hrs 10 nM compound pretreated human ectocervical explant tissue assessed as prolonged inhibition of viral infection post compound removal
|
Human immunodeficiency virus 1
|
90.0
%
|
|
Antiviral activity against HIV-1 Bal infected in 24 hrs 100 to 1000 nM compound pretreated human ectocervical explant tissue assessed as prolonged inhibition of viral infection post compound removal measured after 2 days post compound removal
|
Human immunodeficiency virus 1
|
90.0
%
|
|
Antiviral activity against HIV-1 Bal infected in 24 hrs 100 to 1000 nM compound pretreated human ectocervical explant tissue assessed as prolonged inhibition of viral infection post compound removal measured after 4 days post compound removal
|
Human immunodeficiency virus 1
|
90.0
%
|
|
Antiviral activity against HIV-1 Bal infected in 24 hrs 100 to 1000 nM compound pretreated human ectocervical explant tissue assessed as prolonged inhibition of viral infection post compound removal measured after 6 days post compound removal
|
Human immunodeficiency virus 1
|
90.0
%
|
|
Antiviral activity against HIV-1 SF162 infected in hu-SCID mouse assessed as protection from viral infection at 225 uM
|
Human immunodeficiency virus type 1 (SF162 ISOLATE)
|
85.7
%
|
|
Antiviral activity against HIV-1 SF162 infected in hu-SCID mouse assessed as protection from viral infection at 22.5 uM
|
Human immunodeficiency virus type 1 (SF162 ISOLATE)
|
78.6
%
|
|
Inhibition of RNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase by filter-based filtration assay
|
Human immunodeficiency virus 1
|
370.0
nM
|
|
Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase G190A mutant by filter-based filtration assay
|
Human immunodeficiency virus 1
|
517.0
nM
|
|
Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase Y181C mutant by filter-based filtration assay
|
Human immunodeficiency virus 1
|
570.0
nM
|
|
Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase G190A-81C mutant by filter-based filtration assay
|
Human immunodeficiency virus 1
|
404.0
nM
|
|
Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase DNA-dependent DNA polymerase activity by gel-based primer extension assay
|
Human immunodeficiency virus 1
|
322.0
nM
|
|
Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase G190A mutant by filter-based filtration assay
|
Human immunodeficiency virus 1
|
316.0
nM
|
|
Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase Y181C mutant by filter-based filtration assay
|
Human immunodeficiency virus 1
|
430.0
nM
|
|
Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase G190A-81C mutant by filter-based filtration assay
|
Human immunodeficiency virus 1
|
483.0
nM
|
|
Antiviral activity of wild-type Human immunodeficiency virus 1 isolate 5269 by cell based assay
|
Human immunodeficiency virus 1
|
0.0003
nM
|
|
Antiviral activity of wild-type Human immunodeficiency virus 1 isolate 5331 by cell based assay
|
Human immunodeficiency virus 1
|
0.004
nM
|
|
Antiviral activity of wild-type Human immunodeficiency virus 1 isolate 5512 by cell based assay
|
Human immunodeficiency virus 1
|
0.0105
nM
|
|
Antiviral activity of Human immunodeficiency virus 1 isolate 8116 harboring A98S, G190A mutation in reverse transcriptase by cell based assay
|
Human immunodeficiency virus 1
|
0.0001
nM
|
|
Antiviral activity of Human immunodeficiency virus 1 isolate 8117 harboring A98S, G190A mutation in reverse transcriptase by cell based assay
|
Human immunodeficiency virus 1
|
0.0002
nM
|
|
Antiviral activity of Human immunodeficiency virus 1 isolate 9225 harboring A98S, G190A mutation in reverse transcriptase by cell based assay
|
Human immunodeficiency virus 1
|
0.00035
nM
|
|
Antiviral activity against X4 tropic HIV1 RF infected in human TZM-b1 cells after 2 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
0.84
nM
|
|
Antiviral activity against X4 tropic HIV1 3B infected in human TZM-b1 cells after 2 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
0.53
nM
|
|
Antiviral activity against R5 tropic HIV1 BaL infected in human TZM-b1 cells after 2 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
0.8
nM
|
|
Antiviral activity against R5 tropic HIV1 YU.2 infected in human TZM-b1 cells after 2 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
0.15
nM
|
|
Antiviral activity against X4 tropic HIV1 NL4.3 infected in human TZM-b1 cells after 2 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
0.37
nM
|
|
Antiviral activity against R5 tropic HIV1 R8.BaL infected in human TZM-b1 cells after 2 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
0.19
nM
|
|
Antiviral activity against X4 tropic HIV1 RF infected in human PBMC assessed as inhibition of p24 antigen production after 2 hrs by ELISA
|
Human immunodeficiency virus 1
|
1.48
nM
|
|
Antiviral activity against HIV1 A17 harboring reverse transcriptase K103N, Y181C mutant infected in human TZM-b1 cells after 2 hrs by luciferase assays
|
Human immunodeficiency virus 1
|
8.34
nM
|
|
Antiviral activity against R5 tropic HIV1 YU.2 infected in human PBMC assessed as inhibition of p24 antigen production after 2 hrs by ELISA
|
Human immunodeficiency virus 1
|
1.11
nM
|
|
Antiviral activity against X4 tropic HIV1 NL4.3 infected in human PBMC assessed as inhibition of p24 antigen production after 2 hrs by ELISA
|
Human immunodeficiency virus 1
|
1.15
nM
|
|
Antiviral activity against R5 tropic HIV1 R8.BaL infected in human PBMC assessed as inhibition of p24 antigen production after 2 hrs by ELISA
|
Human immunodeficiency virus 1
|
1.09
nM
|
|
Antiviral activity against wild type HIV1 BaL in human TZM-b1 cells after 48 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
2.0
nM
|
|
Antiviral activity against wild type HIV1 VI829 infected in human TZM-b1 cells after 48 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
2.0
nM
|
|
Antiviral activity against HIV1 BaL expressing reverse transcriptase V106A mutant infected in human TZM-bl cells after 48 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
2.5
nM
|
|
Antiviral activity against HIV1 VI829 expressing reverse transcriptase Y181C mutant infected in human TZM-bl cells after 48 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
10.8
nM
|
|
Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
0.03
nM
|
|
Antiviral activity against multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant infected in human MT4 cells assessed as virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
0.3
nM
|
|
Antiviral activity against HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
1.2
nM
|
|
Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
1.2
nM
|
|
Antiviral activity against HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
333.9
nM
|
|
Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
0.6
nM
|
|
Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
1.2
nM
|
|
Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
1.2
nM
|
|
Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
330.0
nM
|
|
Antiviral activity against HIV1 Ba-L harboring reverse transcriptase V106A mutant
|
Human immunodeficiency virus 1
|
2.5
nM
|
|
Antiviral activity against HIV1 harboring reverse transcriptase VI829/Y181C mutant
|
Human immunodeficiency virus 1
|
10.8
nM
|
|
Antiviral activity against HIV1 harboring reverse transcriptase VI829 mutant
|
Human immunodeficiency virus 1
|
2.0
nM
|
|
Antiviral activity against wild type HIV1 Ba-L
|
Human immunodeficiency virus 1
|
2.0
nM
|
|
Antiviral activity against HIV1 infected in human TZM-b1 cells
|
Human immunodeficiency virus 1
|
2.0
nM
|
|
Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced effect
|
Human immunodeficiency virus 1
|
54.0
nM
|
|
Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced effect
|
Human immunodeficiency virus 1
|
7.0
nM
|
|
Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
|
Human immunodeficiency virus 1
|
39.0
nM
|
|
Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
|
Human immunodeficiency virus 1
|
0.7
nM
|
|
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced effect
|
Human immunodeficiency virus 1
|
1.2
nM
|
|
Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
|
Human immunodeficiency virus 1
|
39.0
nM
|
|
Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
Human immunodeficiency virus 1
|
3.0
nM
|
|
Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
Human immunodeficiency virus 1
|
200.0
nM
|
|
Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
Human immunodeficiency virus 1
|
40.0
nM
|
|
Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
Human immunodeficiency virus 1
|
50.0
nM
|
|
Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
Human immunodeficiency virus 1
|
1.0
nM
|
|
Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
Human immunodeficiency virus 1
|
2.0
nM
|
|
Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
Human immunodeficiency virus 1
|
3.0
nM
|
|
Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
Human immunodeficiency virus 1
|
100.0
nM
|
|
Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
|
Human immunodeficiency virus 1
|
100.0
nM
|
|
Antiviral activity against HIV1 infected in human TZM-bl cells assessed as viral inhibition pre-incubated for 30 mins prior to infection measured after 48 hrs by
|
Human immunodeficiency virus 1
|
2.0
nM
|
|
Antiviral activity against HIV1 NL4.3 infected in human TZM-bl cells incubated for 30 mins prior to infection measured after 48 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
1.3
nM
|
|
Antiviral activity against R5-tropic HIV1 subtype B BaL infected in human TZM-bl cells assessed as viral inhibition pre-incubated for 30 mins prior to infection measured after 48 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
1.4
nM
|
|
Antiviral activity against nevirapine resistant R5-tropic HIV1 subtype C VI829 expressing reverse transcriptase Y181C mutant infected in human TZM-bl cells assessed as viral inhibition pre-incubated for 30 mins prior to infection measured after 48 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
11.0
nM
|
|
Antiviral activity against HIV1 NL4.3 expressing reverse transcriptase K103N mutant infected in human TZM-bl cells assessed as viral inhibition pre-incubated for 30 mins prior to infection measured after 48 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
2.8
nM
|
|
Antiviral activity against HIV1 NL4.3 expressing reverse transcriptase K103N-Y181C mutant infected in human TZM-bl cells assessed as viral inhibition pre-incubated for 30 mins prior to infection measured after 48 hrs by luciferase assay
|
Human immunodeficiency virus 1
|
92.0
nM
|
|
Inhibition of wild-type HIV1 3B reverse transcriptase
|
Human immunodeficiency virus 1
|
1.0
nM
|
|
Inhibition of recombinant HIV1 reverse transcriptase L100I mutant
|
Human immunodeficiency virus 1
|
15.85
nM
|
|
Inhibition of recombinant HIV1 reverse transcriptase K103N mutant
|
Human immunodeficiency virus 1
|
3.981
nM
|
|
Inhibition of recombinant HIV1 reverse transcriptase Y181C mutant
|
Human immunodeficiency virus 1
|
7.943
nM
|
|
Inhibition of recombinant HIV1 reverse transcriptase Y188L mutant
|
Human immunodeficiency virus 1
|
39.81
nM
|
|
Inhibition of recombinant HIV1 reverse transcriptase K103N/Y181C double mutant
|
Human immunodeficiency virus 1
|
39.81
nM
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
18.69
%
|
|
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
|
Homo sapiens
|
730.0
nM
|
|
Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
0.6
nM
|
|
Antiviral activity against HIV-1 IRLL98 harboring reverse transcriptase M41L, D67N, Y181C, M184V, R211K, and T215Y mutants infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
6.0
nM
|
|
Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
12.0
nM
|
|
Antiviral activity against HIV-1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
330.0
nM
|
|
Antiviral activity against HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
2.2
nM
|
|
Antiviral activity against HIV-1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
Human immunodeficiency virus 1
|
54.0
nM
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
25.54
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
9.09
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
6.571
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
2.1
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
3.15
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.15
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
3.15
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
2.1
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.15
%
|
|